Dogwood Therapeutics stock awaits Halneuron trial readout

Dogwood Therapeutics said on Thursday, November 5, that it had completed its Phase 2b study of Halneuron in chemotherapy-induced neuropathic pain and expects top-line results in November. The company announced the update with its third-quarter results in a company release.

Clinical Catalyst Takes Center Stage

The study enrolled 239 patients. Dogwood is also advancing a 12-week open-label extension study, which has enrolled 95 patients and is expected to be completed in early 2027.

Halneuron is being developed for chemotherapy-induced neuropathic pain. The November readout is the next major clinical event for the company and will determine the focus of its planned Phase 3 preparations.

Funding Extends Near-Term Runway

Dogwood reported a third-quarter net loss attributable to common stockholders of 4.9 million US dollars, or 0.14 US dollars per share. The company also said it had closed a 5 million US dollar private placement with Sealbond Limited, a subsidiary of CK Life Sciences and its largest shareholder.

Management said cash on hand together with the placement should support operations through the first quarter of 2027. The financing provides near-term support, while the clinical readout remains central to the company's development plans.

Company Profile

Dogwood Therapeutics is a US biotechnology company developing non-opioid medicines for pain and neuropathy. Its lead clinical program is Halneuron, which is being studied in chemotherapy-induced neuropathic pain. The company is based in Alpharetta, Georgia, and remains in the development stage rather than operating a broad commercial product portfolio.

The broader US equity market can be followed through the S&P 500.

More news and analyses on Dogwood Therapeutics stock.